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Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of
mTOR(mammaliantargetofrapamycin),andclinicaltrialsfortuberoussclerosiscomplex(TSC),neuroﬁbromatosis-1(NF1)and
fragileXsyndrome(FXS),andphosphataseandtensinhomologhamartomasyndromes(PTHS),whichareneurogeneticdisorders
associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched
usingspeciﬁcsearchstrategies.Results/Conclusions.Althoughtraditionallythoughtofasirreversibledisorders,signiﬁcantscientiﬁc
progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic
disorders can be reduced or reversed. This paper revealed signiﬁcant similarities among the conditions. Not only do they share
features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical features—autism, intellectual
disability, cutaneous lesions, and tumors. Although scientiﬁc advances towards discovery of eﬀective treatment in some disorders
have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser
known disorders will become treatable as well.
1.Introduction
Brain plasticity, the developing brain’s ability to change in
response to either positive experiences or negative experi-
ences, is a critical component of pediatric neurology. The
major types of plasticity in the developing brain include
adaptive plasticity—occurs in response to learning or recov-
ering from injury or disability; impaired plasticity—results
from brain injury due to an acquired or neurogenetic dis-
order; maladaptive plasticity—a plastic response leading to a
new disorder; plasticity as the brain’s Achilles’ heel—a mecha-
nism,suchasselectivevulnerabilityofneurons,whichcreates
risk for injury [1]. Basic cellular mechanisms of plasticity
includeoverproductionofneuronsfollowedbyreductionvia
apoptosis [2]; continued production of new cells from stem
cellsin the hippocampus andlateralventricle throughoutlife
[3]; activity-dependent synaptic plasticity through receptor
traﬃcking; activity-dependent production of growth factors;
overproduction of synapses and axodendritic connections
followedbypruning,activity-dependentstabilizationofden-
drites and axons; regulation of DNA expression by epigenetic
regulation [1]. Although there are many disorders associ-
ated with impaired plasticity, this paper will highlight the
clinical features, neurobiology associated with dysregulation
of mTOR, preclinical studies, and clinical trials in tuberous
sclerosis complex (TSC), neuroﬁbromatosis-1 (NF1), and
fragile X syndrome (FXS), as well as phosphatase and tensin
homolog hamartoma syndromes (PTHS), neurogenetic dis-
orders linked by abnormalities in synaptic plasticity and
mTOR (mammalian target of rapamycin) signaling.2 Neural Plasticity
Table 1: Diagnostic criteria.
(a) TSC. Deﬁnite TSC: two major or one major and two minor features; probable; TSC: one major and one minor feature; possible TSC: one major or
t w oo rm o r em i n o rf e a t u r e s
Major features Minor features
Cortical tubers Dental enamel pits
Subependymal nodules Hamartomatous rectal polyps
Subependymal giant cell astrocytoma Bone cysts
Hypomelanotic macules (3 or more) Cerebral white matter radial migration lines
Shagreen patch Gingival ﬁbromas
Facial angioﬁbromas or forehead plaque Nonrenal hamartoma
Multiple renal nodular hamartomas Retinal achromatic patches
Nontraumatic ungual or periungual ﬁbromas “Confetti” skin lesions
Cardiac rhabdomyoma Multiple renal cysts
Pulmonary lymphangiomyomatosis and/or renal angiomyolipomas
(b) NF1. Presence of two or more clinical features
Family history of NF1 Neuroﬁbromas or plexiform neuroﬁbromas
Six or more cafe-au-lait spots Axillary or groin freckling
Lisch nodules Skeletal abnormalities—tibial dysplasia or shin bone thinning
Optic glioma
(c) FXS
Full mutation >200 CGG repeats
Premutation 50–230 CGG repeats
(d) PTHS (Only Cowden syndrome has diagnostic criteria). Cowden syndrome. Operational diagnosis: mucocutaneous lesion alone if: 6 or more facial
papules, 3 or more trichilemmoma; cutaneous facial papules and oral mucosal papillomatosis; oral mucosal papillomatosis and acral keratosis, or 6 or
more palmoplantar keratosis; or two or major criteria, including macrocephaly or adult Lhermitte-Duclos disease; or one major or three minor criteria;
or four minor criteria
Pathognomic criteria Major criteria Minor criteria
Adult Lhermitte-Duclos Breast cancer Intellectual disability
Mucocutaneous lesions Thyroid cancer Other thyroid lesions
Macrocephaly GI hamartomas
Endometrial cancer Fibrocystic breast disease
Lipomas; ﬁbromas
Genitourinary tumors or malformations
EIF4E (No diagnostic criteria).
2. Methods
Pubmed was searched using the following search strategies:
mTOR and/or neurology; mTOR and/or plasticity; mTOR
and/or TSC; mTOR and/or NF1; mTOR and/or FXS; mTOR
and/or PTHS; plasticity and/or neurology; plasticity and/or
TSC; plasticity and/or NF1; plasticity and/or FXS; plasticity
and/or PTHS. Clinicaltrials.gov was searched by disorder
without language or country of origin restrictions for active
studies through 11/30/11.
2.1. Tuberous Sclerosis Complex (TSC)
2.1.1. Clinical Features. Tuberous sclerosis complex (TSC)
has an incidence of 1/6000 and may be deﬁned clinically
by the presence or absence of major and minor features
associated with the disorder and genetically by spontaneous
or inherited mutations in TSC1 or TSC2. Major neuro-
logic features include brain lesions-subependymal nodules,
subependymal giant cell astrocytomas, and cortical tubers,
intractable epilepsy in 60–90% [4–6], autism in up to 61%
[7, 8], intellectual disability in 45% [9], and self-injury in
10% [10]. TSC has also been associated with pulmonary,
cardiac, and cutaneous lesions (Table 1).
2.1.2. Neurobiology of mTOR Dysregulation. Overexpression
of the serine/threonine protein kinase mammalian target of
rapamycin (mTOR) results from disruption of either TSC1
or TSC2. Typically, TSC1 and TSC2 form a complex, which
inhibits Rheb (ras homologue expressed in brain), an acti-
vator of mTOR. The consequences of mTOR overexpression
include abnormally rapid cell growth and hyperactivation
of mRNA translation, which may lead to impaired synaptic
plasticity in TSC [11]( Figure 1).Neural Plasticity 3
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Figure 1: Pathways associated with neurogenetic conditions linked by mTOR and impaired synaptic plasticity. AKT-v—akt murine
thymomaviraloncogenehomolog1;AMPK—adenosinemonophosphatekinase;ATP—adenosinetriphosphate;EIF4E/4EBP1—eukaryotic
translation initiation factor 4E-binding protein 1; ERK—extracellular signal-related kinase; FKB12-FK506—binding protein family;
FMRP—fragile X mental retardation protein; GBL/LST8—(mTOR-associated protein, LST8 homolog); GDP—guanosine diphosphate;
GTP—guanosine triphosphate; GDP—guanosine diphosphate; HIF1α—hypoxia inducible factor 1, alpha subunit IGF—insulin-like growth
factor; IGFR—insulin-like growth factor receptor; IRS—insulin receptor substrate; LKB1—serine threonine kinase 11; mTORC1—
mammalian target of rapamycin complex 1; mTORC2—mammalian target of rapamycin complex 2; MEK—dual speciﬁcity mitogen-
activated protein kinase 1; NF-1—neuroﬁbromatosis 1; P/+ Thr308—phosphorylation of threonine, position 308; P/+ Ser473—
phosphorylation of serine, position 473; PDK1—pyruvate dehydrogenase kinase, isozyme 1; PDK 2—pyruvate dehydrogenase kinase,
isozyme 2; PI3K—phosphoinositide-3-kinase; PIKE—phosphoinositide 3-kinase enhancer; PIP1—p21-activated protein kinase-interacting
protein 1 (PAK1 interacting protein 1); PIP2—phosphatidylinositol 4,5-biphosphate; PIP3—phosphatidylinositol (3,4,5)-triphosphate;
PTEN—phosphatase and tensin homolog; RAS—Ras p21 protein activator 1 or RAS GTPase activating protein; REDD1—regulated in
development and DNA damage responses; RHEB—Ras homologue expressed in brain; RTK—receptor tyrosine kinase; S6K—ribosomal
protein S6 kinase; TSC—tuberous sclerosis complex; VEGF—vascular endothelial growth factor; VHL—von Hippel Lindau.4 Neural Plasticity
2.1.3. Preclinical Models. Impaired synaptic plasticity as a
consequenceofadisruptionineitherTSC1orTSC2hasbeen
supported by results from preclinical studies. Abnormalities
in long-term potentiation (LTP) and long-term depression
(LTD) were found in the Tsc2+/− Eker rat, which carries a
spontaneous germline mutation [12]. Abnormal late-phase
LTP induction and hippocampal-dependent learning deﬁcits
was observed in Tsc2+/− adult mice and improved after
rapamycin treatment [13].
Metabotropic glutamate receptor-mediated long-term
depression (mGluR-LTD) was impaired in Tsc2+/− mice and
related to decreased translation of proteins required for
stabilization of LTD. Potentiation of mGluR5 activity led
to restoration of normal LTD [14]. mGluR-LTD was also
deﬁcient in a neuronal model of Tsc1 [15].
Prolonged neuronal hyperexcitability, typically associ-
ated with epilepsy, has also been supported by recent studies
as a possible mechanism of impaired synaptic plasticity in
TSC [16].Hyperexcitabilityincorticaltubershasbeenlinked
to abnormalities of glutamate receptor expression [17]. This
hyperexcitability was maintained despite the absence of
cortical tubers from brain sections of an individual with
TSC and Tsc1synapsin conditionalknockout mice, a neuronal
model of TSC in an earlier study [18, 19]. An astrocyte-
speciﬁc model of TSC, Tsc1GFAP conditional knockout mice,
was also characterized by abnormally elevated glutamate
[20]. Astrocytic dysfunction in the uptake of extracellular
potassium may explain the hyperexcitability in this model
[21].
2.1.4. Clinical Trials. Guided by preclinical observations,
investigators have completed studies to reduce the burden
of neurologic disease in individuals with TSC. A clinical
trial of everolimus for subependymal giant cell astrocy-
tomas (SEGAs) achieved the primary outcome of reduction
in the size of SEGAs, supporting similar results from a
case series [22–24]. Everolimus is now FDA-approved for
reduction in the size of SEGAs that are nonsurgically
resectable. Positive outcomes from these studies have led
investigatorstoconsiderrapamycinforadditionalneurologic
conditions, such as autism [25]. The ability of everolimus
to improve cognition is currently under investigation
(http://www.clinicaltrials.gov/; NCT01289912).
2.2. Neuroﬁbromatosis 1 (NF1)
2.2.1. Clinical Features. Neuroﬁbromatosis 1 (NF1), a dis-
ease caused by an inherited mutation in NF1, has an
incidenceof1in3500[26].NF1canbediagnosedbyidentiﬁ-
cationofthegeneticmutationorthepresenceoftwoormore
clinical features—family history of NF1; six or more cafe-au-
lait spots; neuroﬁbromas; plexiform neuroﬁbromas; axillary
or groin freckling; Lisch nodules (a hamartomatous nodule
of melanocytes on the iris); skeletal abnormalities such as
tibial dysplasia or thinning of the shin bone; or optic glioma.
Associated conditions include cognitive impairments, pilo-
cytic astrocytomas, and neuropathological abnormalities
characterized by MRI hyperintensities, megalencephaly, and
thalamic lesions. Cognitive impairment is the most common
source of neurological impairment in children with NF1,
aﬀectingasmanyas81%ofchildren[27].Neuropathological
abnormalities associated with impaired cognition have been
identiﬁed in some cases. Megalencephaly associated primar-
ilywithincreasedwhitemattervolumewasidentiﬁedinindi-
viduals with NF1-associated ADHD [28]. Abnormalities in
gray matter volume and enlargement of the corpus callosum
have also been associated with cognitive impairment [29].
NF1 has also been characterized by the presence of MRI
T2-hyperintensities (nonenhancing bright areas of unknown
etiology), sometimes referred to as UBOs (unidentiﬁed
brightobjects).Anearlystudyemployingsiblingcomparison
found distribution of these lesions to be predictive of lower
IQ [30]. Subsequent studies have also supported the role of
these lesions in cognition [31, 32]. A longitudinal proﬁle
revealed changes in these lesions with childhood regression
followed by recurrence in early adolescence [33].
2.2.2. Neurobiology of mTOR Dysregulation. Disinhibited
RAS MAPK signaling underlies the molecular basis of
disease, and mTOR hyperactivity has also been identiﬁed in
preclinical models [34]. NF1 encodes neuroﬁbromin, a GTP-
ase activating protein, which normally leads to inactivation
of Ras. Mutations in neuroﬁbromin lead to overactivation
of Ras activity, followed by enhanced activation of the Ras-
MAPK signaling pathway as well as PI3K and ERK 1/2 which
both inactivate the TSC1/TSC2 complex releasing inhibition
of Rheb and allowing activation of mTOR. However, there
may be pathways leading to dysregulation of mTOR in NF1
that diﬀer from other conditions [34]. mTOR hyperactivity
in Nf1 leads to increased astrocyte proliferation, an eﬀect
not shared by preclinical models of Pten, Tsc1, Tsc2,o r
overexpression of Rheb [35]. Phospho-histone-H3 rather
than phosphor-S6 or Ki67 correlated with response to
rapamycin in Nf1 mice [36]. Neuroﬁbromin also interacts
with caveolin-1 [37]a n dn u c l e o p h o s m i n[ 38].
2.2.3. Preclinical Models. Long-term potentiation was
impaired by increased hippocampal inhibitory transmission
in mice heterozygous for a germline mutation in Nf1
(Nf1+/−). However, restoration of LTP deﬁcits and reversal of
cognitive impairments was achieved with pharmacological
inhibition of Ras using lovastatin, an HMG CoA reductase
inhibitor [39] and BMS 191563, a farnesyltransferase
inhibitor [40]. Farnesyltransferase inhibitors demonstrated
inhibition of Rheb and subsequent inhibition of mTOR
in Tsc1−/− and Tsc2−/− mouse embryonic ﬁbroblasts [41].
Inhibition of ERK also led to restoration of early-phase and
long-term LTP [42].
2.2.4. Clinical Trials. Simvastatin in children with NF1
improved object assembly, a secondary outcome in a ran-
domized trial, but there was no diﬀerence in primary out-
come [43]. Preliminary results of a subsequent of lovastatin
in children with NF1 revealed improvement in verbal and
nonverbal memory [44].Neural Plasticity 5
2.3. Fragile X Syndrome (FXS)
2.3.1. Clinical Features. Fragile X syndrome (FXS) is the
leading cause of inherited intellectual disability and has a full
mutation gene frequency of 1 in 2500 [45, 46]. Associated
neurologic conditions include autism, anxiety, and ADHD
[47, 48]. Deﬁnitive diagnosis relies on genetic conﬁrmation
and individuals may be classiﬁed as full mutation if there
are greater than 200 CGG repeats within the promoter
of the fragile X mental retardation-1 gene (FMR1) and
premutation if there are 50 to 230 repeats [49].
2.3.2. Neurobiology of mTOR Dysregulation. These abnor-
mal CGG repeats result in suppression of FMR1 gene
transcription and subsequently reduced to absent fragile
Xm e n t a lr e t a r d a t i o np r o t e i n( F M R P )[ 50, 51]. Loss of
FMRP releases inhibition of PIKE, which activates PI3K
and leads to increased mTOR activity. The “mGluR theory”
proposes that elevation of group I mGluRs (mGluR1 and
mGluR5) glutamate receptors leading to reduced insertion
of AMPA receptors into the postsynaptic membrane is one
of the central mechanisms of impaired synaptic plasticity in
FXS, and this has been supported in experimental models
[52]. Increased mGluR5 activity and reduced insertion of
AMPA receptors leads to long-term depression (LTD) due to
reduced AMPA-mediated synaptic activity.
2.3.3. Preclinical Models. Using preclinical models, speciﬁc
interactions among synaptic proteins and FMRP have
been identiﬁed. Initially, abnormal synaptic translation of
CaMKIIa, PSD-95, and GluR1/2 mRNAs was observed in
the Fmr1 knockout mouse [53]. Subsequent studies revealed
regulation of expression of PSD-95 by FMRP, miR125a, and
mGluR.
Phosphorylation of FMRP induces the creation of an
AGO2-miR125a complex, which inhibits PSD-95 mRNA.
mGluR stimulation, however, causes dephosphorylation of
FMRP, which leads to activation of translation of PSD-
95. In Fmr1 KO mice, miR125a is reduced in addition to
the reduction in FMRP [54]. In addition to hyperactivity
of group 1 mGluR and mGluR-LTD, abnormally increased
signaling of mTOR in hippocampus was discovered in Fmr1
KO mice, providing a link between mGluR elevation and
abnormalities in synaptic plasticity leading to cognitive
impairment. Loss of FMRP releases inhibition of PIKE,
which activates PI3K and leads to increased mTOR activity
as measured by four methods. Abnormally increased mTOR
leads to an abnormal increase in cap-dependent translation
of synaptic proteins and subsequent abnormalities in synap-
tic plasticity. Inhibition of PI3K activity resulted in normal
levels of phosphorylated mTOR. Increased PTEN activity,
mediated by dephosphorylation, was discovered in Fmr1 KO
mice and may serve as a feedback inhibition to compensate
forabnormallyincreasedPI3KsincePTENdephosphorylates
PI3K, which reduces phosphorylation and activation of Akt
[55].
In a Drosophila model of FXS, treatment with mGluR
antagonists during development resulted in reversal of
neuropathology, abnormalcourtshipbehavior,andimpaired
memory. Partial reversal of impaired memory and abnormal
courtship behavior without change in neuropathology was
seen in treated adults. Conversely, treatment led to impair-
ment in wild-type control ﬂies [56].
Reduction in genetic function of mGluR5, achieved by
crossing Fmr1 mutant mice with heterozygous mGluR5
mutant mice, rescued many of the core phenotypic features
in the Fmr1 KO mouse [57]. Treatment of Fmr1 KO mice
with either an mGluR1 antagonist (JNJ) or an mGluR5
antagonist (MPEP) led to similar, but slightly diﬀerent
neurologic and behavioral improvements. Marble burying,
a measure of repetitive behavior, was reduced without
reduction in activity in Fmr1 KO and WT mice. MPEP
eliminated audiogenic-induced seizures. Motor learning also
improved with MPEP in Fmr1 KO mice. Prepulse inhibition,
a measure of sensorimotor gating, known to be abnormally
increased in Fmr1 KO mice was not aﬀected by JNJ or MPEP
[58]. Abnormalities in prepulse inhibition were linked to
abnormalities in presynaptic short-term plasticity in mice
models of schizophrenia [59].
Prolonged UP states, a marker of cortical hyperexcitabil-
ity in Fmr1 KO mice was found to be due to a non-
translation-related function of mGluR5, and treatment with
MPEP reversed this phenomenon [60]. In addition to long-
term postsynaptic plasticity, abnormalities in short-term
presynaptic plasticity were also identiﬁed in Fmr1 KO mice
and may also contribute to cognitive impairment [61].
Another approach utilized GABAA receptor agonist in Fmr1
KO mice, resulting in restoration of amygdala-based deﬁcits
in neuronal excitability, reduced prepulse inhibition, and
alleviation of hyperactivity [62] .T h eb e h a v i o r a le ﬀects of
genetic reduction of mGluR1 and mGluR5 by 50% were
observed in Fmr1 KO mice. Reduction in mGluR1 led
to decreased activity, whereas reduction in mGluR5 led
to decreased active social behavior and decreased thermal
sensitivity. Neither genetic reduction resulted in changes in
memory, motor responses, sensorimotor gating, audiogenic
seizures, and responses related to anxiety and perseveration
[58].
2.3.4. Clinical Trials. Human studies have led to the iden-
tiﬁcation of the behavioral/cognitive proﬁle of Fragile X as
well an endophenotype of autism in Fragile X distinguished
by social withdrawal [63–65]. Comparison of patients with
FXS with and without autism supported the previously
identiﬁed endophenotype of social withdrawal in FXS-
associated autism by the ﬁnding of decrease in the left
temporal gyriﬁcation index, an indicator of cortico-cortical
connectivity and organization [66]. Recent signiﬁcant sci-
entiﬁc discoveries have culminated in human clinical trials
targeting diﬀerent aspects of the neurobiological impair-
ments in FXS. AFQ056, an mGluR5 antagonist, resulted in
diﬀerent responses dependent upon the methylation status
of FMR1. Patients with full methylation of FMR1 and no
detectable FMR1 mRNA in the blood responded positively
to treatment with improvement in inappropriate speech,
stereotypic behavior, and hyperactivity [67]. Additional
trials focused on antagonizing mGluR5 include a trial of6 Neural Plasticity
fenobam, which reduced anxiety, hyperarousal, improved
accuracy in continuous performance tasks, and prepulse
inhibition of startle [68]; acamprosate, which in three young
adult patients, resulted in improvement in communication
and global clinical improvement (CGI-I) [69]. Results are
pendingfromanopenlabelphaseIstudyofSTX107(Seaside
Therapeutics) and a phase II trial of RO4917523 (Hoﬀman-
LaRoche) (clinicaltrials.gov). Other mechanisms that may
lead to repair of the impaired plasticity associated with FXS
have also been examined. Phospholipase C and glycogen
synthase kinase-3, linked to Gp1 mGluR signaling, have
been targeted using lithium, which resulted in improvement
in cognition and adaptive skills [70]. Ampalex (CX516)
is an ampakine (binds AMPA receptors) that increases
hippocampal LTP by slowing receptor deactivation [71, 72].
Evaluation of ampalex in a placebo-controlled phase II trial
for Fragile X-associated autism did not reveal diﬀerences
in the primary outcome of memory or any of the sec-
ondary outcomes: overall functioning, attention/executive
functioning, language, or behavior [73]. Minocycline, a
broad spectrum antibiotic and analogue of tetracycline,
has been found to have neuronal eﬀects. In C57BL/6J
mice, minocycline increased phosphorylation of GluR1 and
subsequent insertion of AMPA receptors in vivo and vitro
[74]. Study of minocycline in Fmr1 KO mice revealed
behavioral improvement: reduction in anxiety and improved
exploration as well as neuropathological improvement—
dendritic spine maturation associated with inhibition of
abnormallyelevatedmatrixmetalloproteinase-9(MMP-9)in
hippocampal neurons [75] .T h eo b s e r v a t i o n si nFmr1 KO
mice were supported in a Drosophila model of FXS where
treatment with minocycline or genetic elimination of mmp1
reverses synaptic structural abnormalities [76]. Open-label
treatment with minocycline in individuals with FXS led
to signiﬁcant improvement in irritability [77]. Cholinergic
deﬁcits in FXS, conﬁrmed in individuals by 1Hm a g n e t i c
resonance spectroscopy, were targeted using donepezil in an
open label study with noted improvement in continuous
naming, attention diﬃculties, and total ABC score as well
as irritability and hyperactivity [78]. Reduction in glutamate
using riluzole in an open-label study corrected abnormal
activation of ERK; however, improvement in the primary
outcome-repetitive, compulsive behavior was not achieved
[79]. A single-dose, placebo-controlled trial of oxytocin for
social anxiety in FXS resulted in improvement in eye gaze
towardstheexaminerinasocialchallenge[80].Aripiprazole,
an atypical antipsychotic that is a partial D2 and 5-HT1A
agonist as well as a 5-HT2A antagonist, improved scores
on CGI-I and ABC-irritability [81]. Baclofen, a GABAB
receptor agonist, inhibited seizures in Fmr1 mice [82]. A
phase II, randomized double-blind study of arbaclofen has
beencompletedwithresultspending,andaphaseIIIstudyof
arbaclofen is now recruiting (http://www.clinicaltrials.gov/).
2.4. PTEN-Associated Conditions
2.4.1. Clinical Features. Phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) is a phosphatase
which limits cell growth by apoptosis and cell cycle arrest.
Conditions linked by a genetic mutation in PTEN have
been collectively termed phosphatase and tensin homo-
logue hamartoma syndromes (PTHS) and include Juve-
nile Polyposis, Lhermitte-Duclos disease, Bannayan-Riley-
Ruvalcaba, Cowden Syndrome, Proteus-syndrome, and
Proteus-like conditions. Cowden syndrome and Bannayan-
Riley-Ruvalcaba have been associated with autism and
intellectual disability.
Cowden syndrome has an estimated prevalence of
1/200,000 and may be diagnosed by the presence of either
pathognomonic criteria or a speciﬁc combination of major
and minor criteria. Severe and progressive macrocephaly (>2
S.D.) associated with autism should prompt consideration
of the diagnosis and led to publication of the ﬁrst reported
case of Cowden syndrome-associated autism and epilepsy
[83]. A similar pattern with the addition of a lipoma and
thyroid adenoma led to the identiﬁcation of Bannayan-
Riley-Ruvalcaba Syndrome (BRRS) in a nine-year-old girl
[84]. A retrospective review of 114 patients analyzed for
PTEN mutations revealed mutations in 18% of those with
macrocephaly in addition to either ASD or ID [85]. This
contrasts with a PTEN mutation in one of eighty-eight chil-
dren (1%) with macrocephaly and ASD [86]. BRRS does not
have established diagnostic criteria; however, macrocephaly
is usually the most striking feature. Identiﬁcation of Cowden
and Bannayan-Riley-Ruvalcaba syndrome in the same family
raises the possibility of the two syndromes being the same
syndrome with variation in phenotypic expression [87].
Functional analysis of the consequence of PTEN
germline mutations from individuals with autism spectrum
disorders was compared to PTEN germline mutations in
individuals with PTHS in a humanized yeast-based bioassay
and revealed greater preservation of PTEN PIP3 phosphatase
activity in those with ASD [88].
2.4.2. Neurobiology of mTOR Dysregulation. PTEN is impor-
tant in mTOR signaling since it removes a phosphate
from phosphatidylinositol 3,4,5-triphosphate (PIP3). This
conversion from PIP3 to PIP2 negates the activity of PI3K
and results in elevation of mTOR since the processes
downstream—Akt activation, Akt-mediated phosphoryla-
tionandinhibitionofTSC2,releaseinhibitionofRhebwhich
activates mTOR.
2.4.3. Preclinical Models. Evidence of impaired synaptic
plasticityinPTENmutationshasbeenidentiﬁedinPtencon-
ditional knockout mice. Neuropathological features include
enlarged neuronal nuclei and cell bodies, increased density
of dendritic spines, abnormalities in axonal myelination, and
weakening of excitatory synaptic transmission in hippocam-
pal neurons between CA3 and CA1 as evidenced by impaired
EPSPs, normal presynaptic function, and reduced long-term
potentiation [89]. Cre-driven deletion of Pten in cortical and
hippocampal neurons of mice was associated with hyperac-
tivity of the mTOR pathway as well as hypersensitivity to
stimuli, social interaction abnormalities, ectopic dendrites,
increasedaxonalsynapses,andmacrocephalyassociatedwith
neuronal hypertrophy [90].Neural Plasticity 7
Table 2: Mechanisms of impaired synaptic plasticity, mTOR dysregulation, and therapeutic targets.
Condition Gene
(chromosome)
Mechanism of impaired
synaptic plasticity impairment
mTOR
physiology Therapeutic targets
TSC TSC 1 (9) or
TSC2 (16)
↓mGluR-LTD ↑mTOR mTOR antagonists
mGluR 5 agonist
NF1 NF1 (17) ↓LTP↑GABA ↑mTOR Ras antagonists
ERK antagonists
FXS FMR1 (X) ↑mGluR-LTD ↑mTOR
mGluR5 antagonists
mGluR5/mGluR1 genetic reduction
GABAA receptor agonist
PLC/GSK3 antagonist (lithium)
AMPA receptor agonist
MMP 9 antagonist
PTHS PTEN (10) ↓LTP ↑mTOR mTOR antagonists
EIF4E-associated autism EIF4E (4) unknown Downstream
of mTOR None developed
2.4.4. Clinical Trials. A pilot study is now recruiting for
an open label trial of sirolimus, an mTOR inhibitor, in
adultpatientswithCowdensyndrome,tumors,andgermline
PTEN mutations (http://www.clinicaltrials.gov/).
2.5. EIF4E-Associated Autism. Synaptic translation mediated
by EIF4E is a common and ﬁnal process of the pathways
associated with PTEN, mTOR, and FMRP and serves a
critical role in learning and memory [91, 92]. Linkage to
chromosome 4q, the region containing EIF4E has been
shown in genome-wide linkage studies [93, 94]. After iden-
tiﬁcation of a translocation involving the region containing
EIF4E in a young boy with autistic regression, investigators
screened for mutations among families with two autistic
siblings and found EIF4E mutations in two related families
[95].
3. Conclusions
Review of recent literature reveals signiﬁcant advances in
our ability to understand the pathogenesis of several neu-
rogenetic conditions associated with intellectual disability
and autism that have been considered to be idiopathic
and untreatable. In this paper, we have highlighted recent
discoveries in neurogenetic conditions united primarily by
dysregulation of mTOR and evidence of impaired synaptic
plasticity (Table 2). In addition to autism and intellectual
disability, some of these conditions also share an association
with cutaneous lesions and tumor development. Based on
this knowledge, it is reasonable to hope that these disorders
could become treatable in the near future. Investigators have
already begun the process of connected research, as exem-
pliﬁed by the work of Auerbach et al. who simultaneously
examined models of TSC and FXS and created a model by
crossing the two models to discover that the same inter-
vention, modulating metabotropic glutamate receptor 5,
demonstrateseﬃcacyforbothmodelsinopposingdirections
[14].Continuingtoexaminethelinkbetweenthesedisorders
islikelytoleadtoagreaterchanceofdiscoveryforallofthem.
Tools needed to translate basic science research into clinical
trials which yield deﬁnitive results include reﬁned genotypic
and phenotypic characterization, detailed knowledge of the
natural history of the conditions, knowledge of optimal
therapeutic windows, valid biomarkers, and expertise in
clinical trials.
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